The Membrane Bound LRR Lipoprotein Slr, and the Cell Wall-Anchored M1 Protein from Streptococcus pyogenes Both Interact with Type I Collagen

Bober, Marta; Mörgelin, Matthias; Olin, Anders; von Pawel-Rammingen, Ulrich; Collin, Mattias

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0020345

2011

Link to publication

Citation for published version (APA):
Bober, M., Mörgelin, M., Olin, A., von Pawel-Rammingen, U., & Collin, M. (2011). The Membrane Bound LRR Lipoprotein Slr, and the Cell Wall-Anchored M1 Protein from Streptococcus pyogenes Both Interact with Type I Collagen. PLoS ONE, 6(5). https://doi.org/10.1371/journal.pone.0020345

Total number of authors:
5

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
The Membrane Bound LRR Lipoprotein Slr, and the Cell Wall-Anchored M1 Protein from *Streptococcus pyogenes* Both Interact with Type I Collagen

Marta Bober1*, Matthias Mörgelin1, Anders I. Olin1, Ulrich von Pawel-Rammingen2, Mattias Collin1

1 Division of Infection Medicine, Department of Clinical Sciences, Biomedical Center, Lund University, Lund, Sweden, 2 Department of Molecular Biology, Umeå University, Umeå, Sweden

**Abstract**

*Streptococcus pyogenes* is an important human pathogen and surface structures allow it to adhere to, colonize and invade the human host. Proteins containing leucine rich repeats (LRR) have been indentified in mammals, viruses, archaea and several bacterial species. The LRRs are often involved in protein-protein interaction, are typically 20–30 amino acids long and the defining feature of the LRR motif is an 11-residue sequence LxxLxLxxNxL (x being any amino acid). The streptococcal leucine rich (Slr) protein is a hypothetical lipoprotein that has been shown to be involved in virulence, but at present no ligands for Slr have been identified. We could establish that Slr is a membrane attached horseshoe shaped lipoprotein by homology modeling, signal peptidase II inhibition, electron microscopy (of bacteria and purified protein) and immunoblotting. Based on our previous knowledge of LRR proteins we hypothesized that Slr could mediate binding to collagen. We could show by surface plasmon resonance that recombinant Slr and purified M1 protein bind with high affinity to collagen I. Isogenic slr mutant strain (MB1) and *emm1* mutant strain (MC25) had reduced binding to collagen type I as shown by slot blot and surface plasmon resonance. Electron microscopy using gold labeled Slr showed multiple binding sites to collagen I, both to the monomeric and the fibrillar structure, and most binding occurred in the overlap region of the collagen I fibril. In conclusion, we show that Slr is an abundant membrane bound lipoprotein that is co-expressed on the surface with M1, and that both these proteins are involved in recruiting collagen type I to the bacterial surface. This underlines the importance of *S. pyogenes* interaction with extracellular matrix molecules, especially since both Slr and M1 have been shown to be virulence factors.

**Introduction**

*Streptococcus pyogenes* is an important human pathogen. It most commonly causes throat and skin infections, such as pharyngitis and impetigo [1]. It can also cause severe invasive diseases such as sepsis, necrotizing fasciitis and toxic shock syndrome, as well as complications post infection such as rheumatic fever and glomerulonephritis [2]. Surface structures of *S. pyogenes* allow the bacteria to adhere to, colonize and invade mucus membranes and human skin. Some of these structures are M protein, M-like proteins, collagen type I-binding protein (Cpa) and streptococcal fibronectin-binding protein I (SfbI) [3,4].

Mammalian cells have a variety of ways to detect invading pathogens and to alert the immune system. The best known are the Toll-like receptors (TLR), which are transmembrane receptors containing an extracellular leucine rich repeat (LRR) domain. It is the LRR domain in TLRs that is responsible for recognizing diverse microbial components [5]. More recently indentified receptors involved in bacterial recognition are receptors with a carboxyl-terminal LRR domain, a central nucleotide binding and oligomerization domain (NOD). They are implicated in the cytosolic detection of bacterial components, mediated through the LRR domain [6,7]. LRR proteins are also involved in protein-protein interactions such as signal transduction, cell adhesion and apoptosis [8,9]. LRR proteoglycan decorin has been shown to bind to fibrillar collagens. Other examples of LRR proteins are proline arginine-rich end leucine-rich repeat protein (PRELP), chondroadherin (CHAD) and biglycan (10,11).

LRRs are typically 20–30 amino acids long and the defining feature of the LRR motif is an 11-residue sequence LxxLxLxxNxL (x being any amino acid). The number of LRR repeats ranges from 2 to 45 and they are divided into a conserved and variable segment [12,13]. The conserved amino-terminal stretch of 9–12 amino acids forms the a strand and the variable segment is a b strand and the variable segment is a b-strand and the variable segment is a b-strand. The arrangement of the repeats results in a horseshoe-shaped structure with the b-sheet on the concave side and the variable stretches on the convex side [14,15].

Several pathogenic bacteria, both Gram positive and Gram negative express surface proteins with LRR regions. LRR proteins...
have also been identified in viruses, archaea and eukaryotes [15,16]. Internalins of *Listeria monocytogenes* are the most studied bacterial proteins with LRR domains. There are at least 9 proteins in this family and all have been implicated in the invasion of the human cell [17]. The streptococcal leucine rich (Slr) protein is predicted to be a lipoprotein attached to the cell membrane and has been shown to be camouflaged for antibody recognition by the M6 protein [18,19]. Antibodies against Slr are developed during a *S. pyogenes* infection in humans and an *S. pyogenes* strain lacking Slr had lower resistance against neutrophil phagocytosis *in vitro* and was less virulent in a mouse model of infection [18,19]. Slr lacks a LPXTG motif, which links Gram-positive proteins to the cell wall; instead a TLLA lipopoxin is present and acts as a membrane anchoring motif. The Slr protein is similar to virulence proteins of the internalin family of *L. monocytogenes* but there are differences between the proteins. The LRR region in Slr is located in the C-terminal half of the molecule unlike the members of the internalin family in which the LRR region is located in the N-terminal part of the protein. At the end of the N-terminal region there are four histidine triad motifs that are not present in the internalin family of proteins.

Adherence of human pathogens to certain tissue components might reflect preferences for specific sites of infection. Bacterial adhesins that interact with extracellular matrix components such as collagen, fibrinectin, fibrinogen and laminin-related polysaccharides have been identified for both Gram-negative and Gram-positive bacteria. Groups A, B, C, D and G streptococci have all carbohydrates have been identified for both Gram-negative and Gram-positive bacteria with LRR domains. There are at least 9 proteins among the bacterial proteins with LRR family in which the LRR region is located in the N-terminal part of the protein. At the end of the N-terminal region there are four histidine triad motifs that are not present in the internalin family of proteins.

Adherence of human pathogens to certain tissue components might reflect preferences for specific sites of infection. Bacterial adhesins that interact with extracellular matrix components such as collagen, fibrinectin, fibrinogen and laminin-related polysaccharides have been identified for both Gram-negative and Gram-positive bacteria. Groups A, B, C, D and G streptococci have all carbohydrates have been identified for both Gram-negative and Gram-positive bacteria with LRR domains. There are at least 9 proteins among the bacterial proteins with LRR family in which the LRR region is located in the N-terminal part of the protein. At the end of the N-terminal region there are four histidine triad motifs that are not present in the internalin family of proteins.

### Materials and Methods

#### Reagents, bacteria and culture conditions

Bacteria and plasmids used in this study are described in Table 1. The *S. pyogenes* strain of serotype M1 (API) and mutants MB1 and MC25 were cultured in Todd-Hewitt broth (TH) (Difco, Detroit, MI, USA) or TH broth with 0.2% yeast extract (THY) (Oxoid LTD, Hampshire, UK) at 37°C in 5% CO₂ atmosphere, including 150 μg/ml kanamycin for growth of the mutants. Collagen I was purchased from Sigma (St.Louis, MO, USA). Antibodies used in this study were goat anti-rabbit IgG-peroxidase labeled antibody (Bio-Rad, CA, USA) and rabbit anti-collagen I/III antibody (Calbiochem, Darmstadt, Germany). The *S. pyogenes* mutant strain MC25 used in this study was constructed as previously described by Collin et al. [23].

#### Generation of Slr mutant strain

A PCR product was generated from API chromosomal DNA using oligonucleotide primers 5′-ATT-ATT-CTC-GAG-GGT-CTA-TTG-TTA-TCA-T-3′ and 5′-TTG-AGT-AGA-TCT-TAT-AAT-GGA-AGT-G-3′ with XhoI and BglII sites. The XhoI and BglII digested PCR fragment was ligated into XhoI and BglII digested pFW13 and transformed into TOP10 chemically competent cells (Invitrogen, Carlsbad, CA). Purified plasmids were electroporated into competent API cells as previously described [24]. For preparation of competent API cells, the bacteria were cultured over night in THY broth, washed with water and 0.5 M sucrose solution. The electroporation settings were 2.3 kV, 3 μF, 800 Ohms. The electroporated cells underwent phenotypic expression for 2 h in SOGAS solution at 37°C in 5% CO₂. The API recombinants were selected on THY-plates containing 150 μg/ml kanamycin. All the *S. pyogenes* isolates described in Table 1 were tested for the presence of the *slr* gene using standard PCR. DNA was prepared by boiling single colonies in 100 μl of distilled water followed by centrifugation at 10,000 g for 5 min. One μl of supernatant was used as template for PCR with an annealing temperature of 53°C using the oligonucleotide primers 5′-GCT-CCA-ACC-CCA-TTG-CC-ATC-3′ and 5′-TCG-TGA-GCA-TGA-CCT-TCT-TCA-TCG-3′ generating an 1169 bp product.

The *S. pyogenes* wild type strain API and mutants MB1 and MC25 were cultured in THY broth, including 150 μg/ml kanamycin for growth of the mutants, at 37°C in 5% CO₂ atmosphere. The bacterial pellets were resuspended in SDS-PAGE sample buffer and separated by 10% SDS-PAGE and blotted to an Immobilon-PTM PVDF membrane (Millipore, Bedford, MA) according to Towbin et al. [25]. After blotting, the membrane was incubated in 15 ml PBS (140 mM NaCl, 30 mM KCl, 8 mM Na₂HPO₄, 2 mM KH₂PO₄) containing 0.1% Tween 20 (PBST) and 5% skim milk for 30 min at room temperature. After addition of primary antibody from Slr and M1 whole rabbit antiserum at dilution 1:1,000 and 1:20,000, the membrane was incubated at 37°C for 30 min in PBST and 5% skim milk. The filter was washed three times for 5 min in PBST and incubated with goat anti-rabbit IgG-peroxidase labeled antibody diluted 1:3,000 in PBST and 5% skim milk. After incubation the filter was washed three times in PBST and developed with SupersignalWest Pico Chemiluminescent substrate (Thermo Scientific, Rockford, IL) followed by visualization using a Chemidoc XRS imaging system and Quantity One image analysis software (Bio-Rad).
Table 1. Bacteria and plasmids used in this study and the presence of \textit{slr} gene in \textit{S. pyogenes} strains.

| Strain/plasmid | M type | Genotype   | Characteristics | \textit{Slr} gene\(^1\) | Reference or source |
|----------------|--------|------------|-----------------|--------------------------|---------------------|
| Bacteria       |        |            |                 |                          |                     |
| \textit{Streptococcus pyogenes} |        |            |                 |                          |                     |
| AP1            | 1      | Wild type  | M1 serotype     | +                        | WHO Prague collection\(^2\) |
| MC25           | 1      | \textit{emm1}:\textit{Km} | M1 lacking mutant | +                        | [23]                |
| MB1            | 1      | \textit{slr}:\textit{Km} | Slr lacking mutant | -                        | This study          |
| SF370          | 1      | \textit{emm1} | M1 serotype     | +                        | [37,49]             |
| AP6            | 4      | \textit{emm4} | M4 serotype     | +                        | WHO Prague collection |
| AP12           | 12     | \textit{emm12} | M12 serotype    | +                        | WHO Prague collection |
| AP15           | 15     | \textit{emm15} | M15 serotype    | +                        | WHO Prague collection |
| AP23           | 23     | \textit{emm23} | M23 serotype    | +                        | WHO Prague collection |
| AP46           | 46     | \textit{emm46} | M46 serotype    | +                        | WHO Prague collection |
| AP47           | 47     | \textit{emm47} | M47 serotype    | +                        | WHO Prague collection |
| AP53           | 53     | \textit{emm53} | M53 serotype    | +                        | WHO Prague collection |
| Manfredo       | 5      | \textit{emm5}  | M5 serotype     | +                        | [50]                |
| 3686-98        | 1      | \textit{emm1}  | M1 serotype     | +                        | Center for disease control\(^3\) |
| 3688-98        | 2      | \textit{emm2}  | M2 serotype     | +                        | Center for disease control |
| 3671-98        | 3      | \textit{emm3}  | M3 serotype     | +                        | Center for disease control |
| 3670-98        | 4      | \textit{emm4}  | M4 serotype     | +                        | Center for disease control |
| 3667-98        | 5      | \textit{emm5}  | M5 serotype     | +                        | Center for disease control |
| 3693-98        | 6      | \textit{emm6}  | M6 serotype     | +                        | Center for disease control |
| 3261-98        | 9      | \textit{emm9}  | M9 serotype     | +                        | Center for disease control |
| 3904-98        | 11     | \textit{emm11} | M11 serotype    | +                        | Center for disease control |
| 3664-98        | 12     | \textit{emm12} | M12 serotype    | +                        | Center for disease control |
| 3258-98        | 18     | \textit{emm18} | M18 serotype    | +                        | Center for disease control |
| 3913-98        | 19     | \textit{emm19} | M19 serotype    | +                        | Center for disease control |
| 3858-98        | 22     | \textit{emm22} | M22 serotype    | +                        | Center for disease control |
| SS-987         | 24     | \textit{emm24} | M24 serotype    | +                        | Center for disease control |
| 3272-98        | 28     | \textit{emm28} | M28 serotype    | +                        | Center for disease control |
| 3274-98        | 49     | \textit{emm49} | M49 serotype    | +                        | Center for disease control |
| 189-98         | 55     | \textit{emm55} | M55 serotype    | +                        | Center for disease control |
| SS-790         | 57     | \textit{emm57} | M57 serotype    | +                        | Center for disease control |
| 978-97         | 60     | \textit{emm60} | M60 serotype    | +                        | Center for disease control |
| 86-858         | 12     | \textit{emm12} | M12 serotype    | +                        | [51]                |
| KTL3           | 1      | \textit{emm1}  | M1 serotype     | +                        | Finnish Institute for Health |
| KTL9           | 28     | \textit{emm28} | M28 serotype    | +                        | Finnish Institute for Health |
| \textit{Escherichia coli} |        |            |                 |                          |                     |
| TOP10          |        | recA1 endA1 hsdRMS | Cloning strain  |                          | Invitrogen          |
| BL21(DE3)pLysS |        |            | Protein expression strain |            | Novagen             |
| pGEX-6P-1      |        | GST fusion vector |GE Healthcare |            |                     |
| pGEX\textit{slr} |        |            | For expression of GST-Slr fusion protein |This study |                     |
| pFW13          | \textit{kan}\(^a\) | Streptococcal suicide vector | [52] |            |                     |
| pMB801         | \textit{kan}\(^a\) | \textit{slr} knockout plasmid construct | This study |            |                     |
| pCR\textit{\textit{P2.1-TOPO}}\(^\circ\) | \textit{kan}\(^a\), \textit{amp}\(^a\) | Cloning vector | Invitrogen |            |                     |

\(^1\) Presence of the \textit{slr} gene was determined using PCR as described in Material and Methods.
\(^2\) WHO Collaborating Center for Reference and Research on Streptococci, Institute of Hygiene and Epidemiology, Prague, Czech Republic.
\(^3\) National Center for Disease Control reference codes.

doi:10.1371/journal.pone.0020345.t001
microscope operated at 80 kV accelerating voltage, and images were recorded with a Gatan Multiscan 791 CCD camera. A 3 μl aliquot of Slr (1 mg/ml) in TBS buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) was adsorbed onto carbon-coated grids and visualized by electron microscopy as previously described.

Expression pattern of Slr and M1 protein

The S. pyogenes wild type strain AP1 was cultured in THY broth, at 37°C in 5% CO2 atmosphere. Growth was recorded hourly by measurement of OD600 and plotted in KaleidaGraph (Synergy Software, Reading, PA). Samples were collected hourly; Slr and M1 Western blot on cell extracts was performed as described above.

Recombinant expression of Slr and purification of M1 protein

Slr was expressed in Escherichia coli using the GST Gene Fusion System (GE Healthcare). A 2337 base pair slr PCR product was amplified from S. pyogenes genomic DNA using primers 5'-ACT-TTG-GGA-TCC-TGT-CAA-CCA-GCA-3' with a BamHI site (underlined) and 5'-TCT-TAG-CCT-GAG-TTA-GTC-AGC-ATG-3' with an XhoI site (underlined). This fragment was digested with BamHI and XhoI, ligated into pGEX-6P-1 generating plasmid pGEXSlr, that was used to transform E. coli BL21(DE3)-pLys. pGEXSlr/BL21(DE3)pLys was induced with 0.1 mM isopropyl β-D-thiogalactopyranoside and GST-Slr was purified using Glutathione-Sepharose (GE Healthcare) according to manufacturer’s instructions. Purified GST-Slr was used for immunization of rabbits according to standard protocols [29]. The GST tag was removed from GST-Slr by on-column cleavage using Precision protease according to manufacturer’s instructions. Purified GST-Slr was used for immunization of rabbits according to standard protocols [29]. The GST tag was removed from GST-Slr by on-column cleavage using Precision protease according to manufacturer’s instructions. Purified GST-Slr was used for immunization of rabbits according to standard protocols [29].

Sequence analysis and homology modeling of Slr

A homology model of Slr was generated using Multiple Mapping Method with Multiple Templates (MfM) [30] (using Internalin A (PDB 1O6V) [31] as a template. The Slr model was visualized using VMD 1.8.6 (http://www.fiserlab.org/servers/m4t) [30] (using Internalin A (PDB 1O6V) [31] as a template. The Slr model was visualized using VMD 1.8.6 (http://www.fiserlab.org/servers/m4t) [30] (using Internalin A (PDB 1O6V) [31] as a template. The Slr model was visualized using VMD 1.8.6 (http://www.fiserlab.org/servers/m4t) [30] and high resolution images were generated using the Tachyon ray tracer [33].

Lipoprotein analysis using globomycin

AP1 bacteria were cultured in TH over night supplemented with 0, 12.5, 25 and 50 μg/ml of the signal peptide II inhibitor globomycin similarly to what has been described for S. equisimilis, S. equi and S. zooepidemicus [34,35]. Bacteria from 5 ml cultures were pelleted by centrifugation and resuspended in 200 μl PBS. Bacteria were lysed by addition of 100 U of the bacteriophage lysin PhC [36] for 10 min at room temperature followed by addition of a final concentration of 25 μg/ml of ribonuclease A and deoxyribonuclease (Sigma) and incubation for 10 min at room temperature. Samples were centrifuged for 10 min at 14,000 × g at 4°C. Pellets were resuspended in SDS-PAGE sample buffer and separated on 10% SDS-PAGE followed by transfer to PVDF membranes and anti-Slr Western blot as described above.

Absorption of collagen type I to S. pyogenes strains

The strains AP1, MB1 and MC25 were grown in THY to OD600 = 0.8, with 150 μg/ml kanamycin for growth of the mutants, at 37°C in 5% CO2 atmosphere. The bacteria were washed with PBST and diluted to 2 × 10^7 cfu/ml solution. 200 μl of the bacterial solution were incubated with 100 μg collagen I for one hour at room temperature. Aliquots of the solution were taken for electron microscopy visualization as previously described in Bober et al [27]. The bacterial solution was washed three times with PBST and the bound collagen was eluted from bacterial surface by incubation with 0.1 M glycine, pH 2.0 for 20 min. The bacteria were removed by centrifugation, 1300 xg for 10 minutes, and the supernatant was neutralized by addition of 1 M Tris base.

In vitro binding studies

The strains AP1, MB1 and MC25 were grown in THY to OD600 = 0.8, with 150 μg/ml kanamycin for growth of the mutants, at 37°C in 5% CO2 atmosphere. The bacteria were washed with PBST and diluted to 2 × 10^7 cfu/ml solution. 200 μl of the bacterial solution were incubated with 100 μg collagen I for one hour at room temperature. Aliquots of the solution were taken for electron microscopy visualization as previously described in Bober et al [27]. The bacterial solution was washed three times with PBST and the bound collagen was eluted from bacterial surface by incubation with 0.1 M glycine, pH 2.0 for 20 min. The bacteria were removed by centrifugation, 1300 xg for 10 minutes, and the supernatant was neutralized by addition of 1 M Tris base.

Surface plasmon resonance (SPR) interaction analysis

Collagen I, diluted to 10 mg/liter in 10 mM sodium acetate (pH 4), was immobilized via amine coupling to CM3 sensorchip
flow chambers (GE Healthcare) at moderate response levels (e.g. 1500 RU). Briefly, Collagen was mixed with freshly prepared 100 mM N-hydroxysuccinimide and 400 mM N-ethyl-N’-(dimethylaminopropyl)carbodiimide in equal volumes, and capping of unreacted carboxymethyl sites was achieved by a 1 M ethanolamine (pH 9) injection. A flow chamber subjected to the immobilization protocol but without any addition of protein was used as control (blank) for each experiment. Slr and M1 proteins respectively, were sequentially diluted 2-fold in running buffer (10 mM HEPES, 150 mM NaCl, and 0.005% Surfactant P20 (GE Healthcare) pH 7.5) and injected over the collagen surface starting at 500 nM and 35 μl/min. Bacterial cell suspensions were diluted 2-fold into PBS for injections in PBS in sequence starting from 2×10^9 cfu/ml solution. Binding was monitored in a BIAcore 2000 instrument. Between experiments, the collagen surfaces were strictly regenerated with multiple pulses of 2 M NaCl and 1.5 M glycine-HCl pH 2.0 followed by an extensive wash procedure using running buffer or PBS, respectively. After x-axis and y-axis normalization of obtained data, the blank bulk refraction curves from the control flow chamber of each injected concentration or experiment were subtracted. Binding curves were displayed and where applicable, the association (K_a) and dissociation (K_d) rate constants were determined using the BIA Evaluation 4.1 software and its equation for 1:1 Langmuir binding.

**Results**

Slr is a horseshoe shaped LRR lipoprotein

The slr gene encoding the *S. pyogenes* LRR protein Slr is present in 32/32 strains of 24 different M serotypes as determined by PCR (Table 1) and is also present in all currently sequenced *S. pyogenes* genomes. The slr gene in strain AP1 was cloned and sequenced using oligonucleotide primers based on the genome sequence from the M1 strain SF370 (Accession no. NC_002737) [37]. Sequenc-

---

**Figure 1. Characteristics of the Slr protein.** A: Schematic comparison of the InlA from *L. monocytogenes* and Slr. The identity and similarity between the two LRR regions are stated. The cell wall anchoring motif for InlA and the signal peptide II recognition motif for Slr are indicated as well as the histidine triad motifs. B: Sequence alignments of the two groups of LRRs (A and B repeats) in Slr and comparison of the LRR consensus sequences of Slr and InlA.

doi:10.1371/journal.pone.0020345.g001
ing of this gene revealed an ORF encoding a 793 amino acid protein that is 99% identical to the predicted Slr protein from SF370. The sequences of the Slr from AP1 and the corresponding gene *slr*, have been deposited in Genbank under the accession no. HQ908654. Slr contains a 21 amino acid putative N-terminal signal sequence ending with the amino acid sequence TLIA. This is the recognition sequence for signal peptidase II that allows for lipid modification of the resulting amino-terminal cysteine and insertion into the cellular membrane. In between amino acid 22 and 421 are four histidine triad motifs, that are not present in InlA of *L. monocytogenes*. There are 13 LRRs in Slr spanning over amino acid numbers 421–705 forming the β-sheets compared to 15 LRRs in InlA. The carboxyl terminal end of Slr contains histidine rich repeat sequences, but lacks a cell wall anchoring motif, while InlA carries a classical LPtTG cell wall anchoring motif (Figure 1A). The LRR in Slr resembles the consensus motif of the LRR region in InlA (Figure 1B). To confirm the horseshoe shape of the protein, Slr was visualized by electron microscopy. The Slr is pointed out by arrows and the shape is well visible supporting a horseshoe like conformation of Slr (Figure 2A).

Figure 2. Visualization and confirmation of the LRR lipoprotein Slr. A: Slr protein visualized by electron microscopy showing the typical horseshoe shape of a LRR protein. Scale bar = 25 nm. B: a homology model of Slr using InlA as the template. The 11 LRRs forming β-sheets in yellow, α-helices in blue, and loops in turquoise. C: SDS-PAGE analysis of recombinantly expressed GST-Slr and Slr with the GST tag cleaved off. D: Western blot analysis, using anti-Slr antibodies, of bacterial cell extracts from AP1 bacteria grown in the presence of increasing amounts of the signal peptidase II inhibitor globomycin as indicated.
doi:10.1371/journal.pone.0020345.g002
Homology modeling of Slr using InlA as the template further supported the protein’s structure. The modeled LRRs forming the β-sheets (blue) are suggested to be the protein-protein interaction sites (Figure 2B).

**Slr is a surface lipoprotein**

The Slr protein was expressed in *E. coli* using the GST Gene Fusion system and was used in several *in vitro* experiments (See Material and Methods). GST-Slr and Slr were separated on a SDS-PAGE for size and purity control. The GST-Slr has an apparent size of 110 kDa and Slr of approximately 85 kDa (Figure 2C). To confirm that Slr is a lipoprotein, a globomycin inhibition assay was performed. The maturation of lipoproteins is governed by signal peptidase II that removes signal peptides in the NH2-terminal signal sequence. This step is inhibited by globomycin, resulting in a surplus of signal peptides and thus an increased molecular size (Figure 2D), confirming that Slr is a lipoprotein. To investigate the role of Slr on the surface of *S. pyogenes*, we constructed a Slr mutant by single crossover mutagenesis of the AP1 strain of M1 serotype. A 505 bp promotorless fragment of the *slr* gene was cloned into multiple cloning site I of pFW13, resulting in vector pMB01 (Figure 3A). One mutant strain denoted MB1 was chosen for further analysis. Correct insertion of pMB01 was confirmed by PCR using gene- and plasmid specific primers (Figure 3A, primer 1–4, data not shown). To confirm *slr* disruption in MB1 and the Slr and M1 expression in AP1 and MC25, protein extracts from AP1, MB1 and MC25 cell pellets were analyzed by immunoblotting using anti-Slr and anti-M1 antibodies. A strong signal was detected in the AP1 pellet for both Slr and M1 protein. The only detectable signal in MB1 was for the M1 protein while in MC25 only Slr expression was detected (Figure 3B). Further mutant strain analysis and surface protein localization was done using gold labeled F(ab’)2 fragments of anti-Slr (small gold) and anti-M1 (large gold) IgG. The F(ab’)2 fragments were incubated with wild type and mutant strains and analyzed by negative staining and transmission electron microscopy. The AP1 strain, expressing both Slr and M1 protein, bound both M1 and Slr antibodies simultaneously, (Figure 3C) whereas the mutant MB1 strain only showed binding of M1 antibodies verifying that the Slr protein is not expressed on the surface (Figure 3C).

![Figure 3](https://www.plosone.org/article/funding?doi=10.1371/journal.pone.0020345.g003)

**Figure 3.** Slr gene disruption, mutant strain analysis and protein localization by electron microscopy. A: Schematic representation of the mutagenesis strategy used to disrupt *slr* in *S. pyogenes* strain AP1. B: SDS-PAGE and Western blot analysis, using antibodies against Slr and M1, of bacterial cell extracts of the mutant strains MB1 and MC25, and wild type bacteria AP1. C: Wild type strain AP1, mutant strain MB1 and mutant strain MC25 incubated with gold labeled F(ab’)2 fragments of anti-Slr (small gold particles) and anti-M1 (big gold particles) IgG. The dots represent binding of the F(ab’)2 fragments to the Slr and M1 protein on the bacterial surface. Arrowheads without arrows indicate binding of anti-Slr antibodies, and complete arrows indicate binding of anti-M1 antibodies in all three panels. Scale bar = 100 nm.

*doi:10.1371/journal.pone.0020345.g003*
MC25 strain only exhibited binding of Slr antibodies, showing that the M1 protein is not present on the bacterial surface (Figure 3C). The expression pattern of Slr and M1 was investigated in the wild type strain AP1. The growth was plotted as OD_{620} versus the incubation time (Figure 4A), and samples were taken for Western blot analysis. Slr protein can be detected from hour 6 (approx. OD\textsubscript{620} = 0.4) and declines at hour 9 (approx. OD\textsubscript{620} = 0.8), while M1 can be detected from hour 2 (approx. OD\textsubscript{620} = 0.05) (Figure 4B) and starts to be degraded at hour 7 (data not shown). Taken together, these results indicate that Slr is an abundant membrane bound lipoprotein that is co-expressed on the surface with the M1 protein in early stationary growth phase.

**Slr and M1 binds to collagen type I**

Previous results implicated that M proteins can interact with collagens (data not shown). Since it has been stipulated that LRRs have collagen binding capacity and since Slr is co-expressed with M protein on the bacterial surface there are reasons to investigate whether Slr can contribute to the collagen binding capacity of *S. pyogenes*. Therefore, we analyzed a possible Slr- collagen interaction. Wild type AP1 (expressing both M protein and Slr), mutant strain MB1 (lacking Slr protein), and MC25 (lacking M1 protein) bacteria were incubated with collagen I and the bound collagen was eluted with low pH glycine. The eluted proteins were immobilized on a PDVF membrane and anti-collagen Western blot was performed. The wild type AP1 strains exhibited strongest binding ability towards collagen I, while MB1 and MC25 strain showed diminished binding capacity (Figure 5A). The eluted collagen I from the AP1, MB1 and MC25 strains was also separated on 3–12% SDS-PAGE with collagen I as a standard and similar results could be observed as for anti-collagen Western blot, with AP1 showing a higher binding of collagen I than both MC25 and MB1 (Figure 5B). In order to further establish the collagen binding capacity of strains AP1, MB1 and MC25, a binding assay with radiolabeled collagen I was performed. The strains were incubated with \textsuperscript{125}I labeled collagen I, unbound collagen was removed by centrifugation and the radioactivity value of bound collagen was measured. All strains exhibited binding toward collagen I with the binding capacity of 36.8% for AP1, 36.1% for MB1 and 33.2% for MC25 (Figure 5C). The binding of collagen to the bacterial strains was also visualized by electron microscopy, where association of collagen I could be observed for all three strains with a tendency of less accumulation in MB1 and MC25 (Figure 5D). To determine the influence of collagen denaturation...
during SDS-PAGE on the Slr binding, non-denatured and guanidine hydrochloride-denatured collagen I was examined in a slot blot experiment. The same procedure was used to determine that the binding was not caused by the GST-tag on Slr. The slot blot experiment showed no interaction between collagen I and the GST-tag (data not shown). The radiolabeled Slr bound to both collagen preparations in a similar manner (Figure 6A). Further in vitro interaction between Slr and both monomer and fibrillar collagen I was investigated. Gold labeled Slr (the dots) and monomer collagen I show four binding sites. The dots are bound to C- and N terminal as well as 70 respectively 100 nm further in on the collagen (Figure 6B, panel I). More detailed analysis is

![Figure 5. Absorption of collagen type I to S. pyogenes strains. A: After incubation of mutant strains MB1, MC25 and wild type AP1 strain with collagen I, low pH eluates from bacteria were immobilized on a PVDF membrane and detected using anti-collagen antibodies. The amount of collagen I eluate applied on the membrane is indicated to the left. B: The bacterial eluates described in 4A were separated on SDS-PAGE and stained with Coomassie Brilliant Blue. Visible are the α1 (134 kDa) and α2 (130 kDa) chains indicated with arrows. C: Binding in percentage of 125I labeled collagen I to the bacterial strains AP1, MB1 and MC25. Experiments were performed in quadruples at three independent time points. D: Interaction between S. pyogenes strains and monomeric collagen. Collagen I was incubated with AP1, MB1 and MC25 and visualized by electron microscopy. Arrows point to collagen I monomers. Scale bar = 100 nm. doi:10.1371/journal.pone.0020345.g005](image)
required to identify the specific site of interaction. The collagen I fibril is composed of triple helices overlapping each other, resulting in a variation of triple helical thickness in the molecule. The short span between light strands represents the overlap region where the collagen triple helices overlap each other, while the dark span represents the gap region where the gap between collagen helices occurs. Binding can be observed in both regions, but is mostly concentrated to the overlap region (Figure 6B, panel II). These experiments were also executed with gold-labeled GST. There was no interactions between GST and monomeric or fibrillar collagen I (data not shown). The binding of Slr and M1 protein as well as the AP1, MB1 and MC25 strains to collagen I was investigated using surface plasmon resonance. Slr and M1 showed a dose-dependent binding to collagen I with a \( K_D \) of 12 nM and 54 nM, respectively (Figure 7A and B). The bacterial strains AP1, MB1 and MC25 also showed a dose-dependent binding to collagen I (Figure 7C–E). Taken together, these results suggest that both Slr and M1 protein can bind collagen I, both when in purified form and in a bacterial surface context. Slr has a somewhat higher affinity towards collagen I than M1.

Discussion

*S. pyogenes* is a human pathogen responsible for a variety of diseases, from common infections to life-threatening conditions. One of the most studied virulence factors of *S. pyogenes* is the cell wall anchored M protein. It is involved in adherence to human epithelial cells, such as buccal cells and epidermal keratinocytes [38,39]. The M protein is also intimately linked to antiphagocytic properties and intracellular survival in phagocytic cells [40,41]. Of particular interest for the present study is that the M6 protein present on the surface of *S. pyogenes* of M6 serotype has been suggested to camouflage the LRR lipoprotein Slr from Slr antibody recognition [19].

Lipoproteins from Gram-positive bacteria are not as well studied as cell wall anchored proteins, but several recent studies have suggested that lipoproteins also are important for immune evasion and adherence during colonization and infection. Furthermore, several lipoproteins have shown promise as vaccine candidates [42]. Previously described lipoproteins of *S. pyogenes* are linked to metal transport as acquisition, most of them belong to ABC transport systems and some have been shown to be virulence factors in animal models of infection [43,44,45,46].

Proteins containing LRRs vary widely in functions and are found in both prokaryotes and eukaryotes, but the known bacterial LRR proteins, especially from *Listeria* species, are important virulence factors that mediate adhesion and cellular invasion through protein-protein interactions [17]. The slr gene encoding Slr can be found in all 32 strains of 23 different M serotypes *S. pyogenes* used in this study, as well as in all currently sequenced *S. pyogenes* genomes. The apparent conservation of the slr gene, the previous finding that patients with *S. pyogenes* infections seroconvert to the Slr protein and the fact that Slr negative mutants are attenuated in animal model and contribute to phagocytosis resistance [18], warrant further investigation of the function of Slr and possibly also exploration of Slr as a vaccine candidate.

Slr and M1 protein expression on the bacterial surface reach their peaks at different time points during the logarithmic growth phase and M1 starts to be degraded before Slr. However, during a substantial amount of time in late logarithmic growth phase, both proteins are present at the bacterial surface. This expression pattern could be similar in an *in vivo* situation, where Slr and M1 surface exposure results in optimal adherence to host tissue. Direct binding experiments indicate that Slr binds strongly to collagen I, both in native and denatured form. This could suggest a fairly limited site of interaction and/or a protein-protein interaction that

Figure 6. Binding of Slr to immobilized collagen I. A: Collagen I denatured with 4 M guanidine hydrochloride (+) and non-denatured collagen I (−) were applied to a PVDF membrane and incubated with radiolabeled Slr. The amount of collagen is indicated to the right. B: Binding of gold labeled Slr (the dots) and collagen I using electron microscopy. The dots are bound to C- and N terminal as well as 70 respectively 100 nm further in on the monomeric collagen I (panel I). The short span between light strands represents the overlap region, while the dark span represents the gap region on a collagen I fibril. Binding can be observed in both regions, but is mostly concentrated to the overlap region (panel II). Scale bar = 100 nm. doi:10.1371/journal.pone.0020345.g006
is not dependent on the three-dimensional structure of collagen I. In vitro binding assay with the wild type and mutant strains showed that elimination of either Slr or the M1 protein on the bacterial surface did not have a major effect on the strains’ total capacity to bind collagen I. A similar binding pattern of Slr and M1 toward collagen could also be observed in direct binding assays, leading to a conclusion that both proteins can use collagen as a ligand.

Interestingly, we did not observe that M1 protein inhibited the binding of gold-labeled Slr antibodies to Slr on the bacterial surface as previously described for the M6 protein [19]. In fact, gold-labeled anti-M1 and anti-Slr antibodies could bind simultaneously to the bacterial surface (Fig. 3C). This observation, in combination with observed collagen binding to both proteins on the surface of the bacteria, suggest that under the conditions studied here, M1 and Slr are simultaneously accessible for some protein-protein interactions on the bacterial surface. On the other hand, elimination of either Slr or the M1 protein from the bacterial surface might reveal additional binding sites toward collagen I on the remaining protein in concordance with the camouflaging described by Waldemarsson et al [19]. This might...
explain why there was not a major reduction in total collagen I binding capacity of the Srl and M1 mutants compared to the wild type strain.

Another feature of Srl are the four histidine triad motifs in the N-terminal part of the molecule, which are absent in InLA of L. monocytogenes. Such motifs have been identified in four proteins of *Streptococcus pneumoniae* and might be involved in metal or nucleoside binding [47]. Furthermore, such histidine triad proteins in *S. pneumoniae* have been shown to alter complement deposition of the bacterial surface [48]. Therefore, enzymatic or other functions than collagen binding of Srl, cannot be excluded.

In conclusion, we have established that Srl is an abundant membrane bound horseshoe shaped LRR lipoprotein from *S. pyogenes* that, both alone and in concert with M1 protein, interacts strongly with collagen I. The multiple interactions with collagen I through Srl and M protein, indicate that collagen binding is an important feature of *S. pyogenes*. Therefore, further studies elucidating the regulation of, and possible inhibition/co-operation between Srl and M proteins will be important in understanding how S. pyogenes interacts with the extracellular matrix during colonization and infection.

**Acknowledgments**

Maria Baumgarten and Ulla Johansson are acknowledged for excellent technical assistance. We are most grateful to Drs. Daniel Nelson and Vincent A. Fischetti (Rockefeller University, New York) for providing PyG, Dr. Masatoshi Ikukai (International University of Health and Welfare, Tochigi, Japan) for providing glomocycin, and Dr. Lars Björck (Lund University, Sweden) for providing GST-IdeS.

**Author Contributions**

Conceived and designed the experiments: MB MC AIO MM. Performed the experiments: MB MC AIO MM. Analyzed the data: MB MC. Contributed reagents/materials/analysis tools: UvP-R. Wrote the paper: MB MC.

**References**

1. Cunningham MW (2000) Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13: 470–511.
2. Dunka K, Rohde M, Jenssen WT, Kaplan EL, Chhatwal GS, et al. (2003) Rheumatic fever-associated *Streptococcus pyogenes* isolates aggregate collagen. J Clin Invest 111: 1905–1912.
3. A˚kesson P, Schmidt KH, Cooney J, Björck L, (1994) M1 protein and protein H: IgGFe- and albumin-binding streptococcal surface proteins encoded by adjacent genes. Biochem J 300 (Pt 3): 877–886.
4. Kreikemeyer B, Nakata M, Oechsle S, Gieselwindner C, Normann J, et al. (2003) *Streptococcus pyogenes* collagen type II-binding Cfa surface protein. Expression profile, binding characteristics, biological functions, and potential clinical impact. J Biol Chem 278: 33229–33239.
5. Jin MS, Lee JO (2000) Structures of TLR-ligand complexes. Curr Opin Immunol 12: 418–419.
6. Bonnici L, Wern C (2007) Role of Nods in bacterial infection. Microbes Infect 9: 629–636.
7. Martimón F, Tschopp J (2005) NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26: 447–454.
8. Kresse H, Schoberr E (2001) Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 189: 266–274.
9. Hohenester E, Hussain S, Howitt JA (2006) Interaction of the guidance molecule Slit with cellular receptors. Biochem Soc Trans 34: 418–421.
10. Park JM, Allen BL, McGavin MJ, Hook M (1994) MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 48: 585–617.
11. Scott JE (1988) Proteoglycan-ﬁbril collagen interactions. Biochem J 252: 394–403.
12. Bella J, Hindle KL, McEwan PA, Lovell SC (2008) The leucine-rich repeat and motif IV to FOG, a novel matrix adhesin interacting with collagen I in vivo. J Biol Chem 283: 1670–1679.
13. Nitsche DP, Johansson HM, Frikk IM, Mörgelin M (2006) Streptococcal protein POG, a novel matrix adhesive interacting with collagen I in vivo. J Biol Chem 281: 1670–1679.
14. Kostrynska M, Schalen C, Wadström T (1989) Specific binding of collagen type IV to *Streptococcus pyogenes*. FEMS Microbiol Lett 50: 229–233.

**The Streptococcal Lipoprotein Slr Binds Collagen I**
44. Zhu H, Liu M, Lei B (2008) The surface protein Shr of *Streptococcus pyogenes* binds heme and transfers it to the streptococcal heme-binding protein Shp. BMC Microbiol 8: 15.
45. Sook BR, Block DR, Sumithran S, Montanez GE, Rodgers KR, et al. (2008) Characterization of SiaA, a streptococcal heme-binding protein associated with a heme ABC transport system. Biochemistry 47: 2678–2688.
46. Weston BF, Brenot A, Caparon MG (2009) The metal homeostasis protein, Lap, of *Streptococcus pyogenes*, is necessary for acquisition of zinc and virulence. Infect Immun 77: 2840–2848.
47. Adamou JE, Heinrichs JH, Erwin AL, Walch W, Gayle T, et al. (2001) Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 69: 949–958.
48. Melin M, Di Paolo E, Tikkanen L, Jarva H, Neyt C, et al. (2010) Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun 78: 2089–2098.
49. Novoselov AN, Ferretti JJ (1996) Physical and genetic chromosomal map of an M type 1 strain of *Streptococcus pyogenes*. J Bacteriol 178: 5346–5349.
50. Holden MT, Scott A, Cherevach I, Chillingworth T, Churcher C, et al. (2007) Complete genome of acute rheumatic fever-associated serotype M5 *Streptococcus pyogenes* strain manfredo. J Bacteriol 189: 1473–1477.
51. Hauer AR, Schlaweirt PM (1999) Nucleotide sequence of the streptococcal pyogenic exotoxin type B gene and relationship between the toxin and the streptococcal proteinase precursor. J Bacteriol 172: 4536–4542.
52. Podbielski A, Spellerberg B, Woschlnak M, Pohl B, Luticken R (1996) Novel series of plasmid vectors for gene inactivation and expression analysis in group A streptococci (GAS). Gene 177: 137–147.